Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging Therapies for Patients With Difficult-to-Treat Migraine.

Literature DB >> 30271106

Emerging Therapies for Patients With Difficult-to-Treat Migraine.

Abstract

The landscape of migraine therapy is set to change with the introduction of new classes of medications aimed at providing options for patients who have not responded to previous therapies. However, the pricing of the new agents will likely be a key determinant in the extent of their use in clinical practice.

Entities: Disease Species

Year: 2018 PMID： 30271106 PMCID： PMC6152700

Source DB: PubMed Journal: P T ISSN： 1052-1372

17 in total

1. Fremanezumab for the Preventive Treatment of Chronic Migraine.

Authors: Stephen D Silberstein; David W Dodick; Marcelo E Bigal; Paul P Yeung; Peter J Goadsby; Tricia Blankenbiller; Melissa Grozinski-Wolff; Ronghua Yang; Yuju Ma; Ernesto Aycardi
Journal: N Engl J Med Date: 2017-11-30 Impact factor: 91.245

2. A Controlled Trial of Erenumab for Episodic Migraine.

Authors: Peter J Goadsby; Uwe Reuter; Yngve Hallström; Gregor Broessner; Jo H Bonner; Feng Zhang; Sandhya Sapra; Hernan Picard; Daniel D Mikol; Robert A Lenz
Journal: N Engl J Med Date: 2017-11-30 Impact factor: 91.245

3. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.

Authors: Virginia L Stauffer; David W Dodick; Qi Zhang; Jeffrey N Carter; Jessica Ailani; Robert R Conley
Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302

4. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).

Authors: Michael Stokes; Werner J Becker; Richard B Lipton; Sean D Sullivan; Teresa K Wilcox; Leandra Wells; Aubrey Manack; Irina Proskorovsky; Jonathan Gladstone; Dawn C Buse; Sepideh F Varon; Peter J Goadsby; Andrew M Blumenfeld
Journal: Headache Date: 2011 Jul-Aug Impact factor: 5.887

5. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Authors: David W Dodick; Stephen D Silberstein; Marcelo E Bigal; Paul P Yeung; Peter J Goadsby; Tricia Blankenbiller; Melissa Grozinski-Wolff; Ronghua Yang; Yuju Ma; Ernesto Aycardi
Journal: JAMA Date: 2018-05-15 Impact factor: 56.272

6. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

Authors: Stewart Tepper; Messoud Ashina; Uwe Reuter; Jan L Brandes; David Doležil; Stephen Silberstein; Paul Winner; Dean Leonardi; Daniel Mikol; Robert Lenz
Journal: Lancet Neurol Date: 2017-04-28 Impact factor: 44.182

Review 7. The CGRP Pathway in Migraine as a Viable Target for Therapies.

Authors: Lars Edvinsson
Journal: Headache Date: 2018-05 Impact factor: 5.887

8. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study.

Authors: Faisal Mohammad Amin; Mohammad Sohail Asghar; Anders Hougaard; Adam Espe Hansen; Vibeke Andrée Larsen; Patrick J H de Koning; Henrik B W Larsson; Jes Olesen; Messoud Ashina
Journal: Lancet Neurol Date: 2013-04-09 Impact factor: 44.182

9. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.

Authors: David W Dodick; Messoud Ashina; Jan Lewis Brandes; David Kudrow; Michel Lanteri-Minet; Vera Osipova; Kerry Palmer; Hernan Picard; Daniel D Mikol; Robert A Lenz
Journal: Cephalalgia Date: 2018-02-22 Impact factor: 6.292

Review 10. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.

Authors: Smriti Iyengar; Michael H Ossipov; Kirk W Johnson
Journal: Pain Date: 2017-04 Impact factor: 7.926

1 in total

1. Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment.

Authors: Chi-Chung Li; Tiffini Voss; Ken Kowalski; Bei Yang; Huub Jan Kleijn; Christopher J Jones; Rolien Bosch; David Michelson; Matthew DeAngelis; Yang Xu; Iris Xie; Prajakti A Kothare
Journal: Clin Transl Sci Date: 2020-01-16 Impact factor: 4.689

1 in total